CN103242413B - Lupane三萜系衍生物及其药学用途 - Google Patents

Lupane三萜系衍生物及其药学用途 Download PDF

Info

Publication number
CN103242413B
CN103242413B CN201310014849.XA CN201310014849A CN103242413B CN 103242413 B CN103242413 B CN 103242413B CN 201310014849 A CN201310014849 A CN 201310014849A CN 103242413 B CN103242413 B CN 103242413B
Authority
CN
China
Prior art keywords
independently
compound
alkyl
reaction
dichloromethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310014849.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103242413A (zh
Inventor
陆峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai de Novo Pharmatech Co Ltd
Jiangxi Qingfeng Pharmaceutical Co Ltd
Original Assignee
FENG QIAODI
Jiangxi Qingfeng Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201310014849.XA priority Critical patent/CN103242413B/zh
Application filed by FENG QIAODI, Jiangxi Qingfeng Pharmaceutical Co Ltd filed Critical FENG QIAODI
Priority to BR112014018953A priority patent/BR112014018953A8/pt
Priority to US14/374,832 priority patent/US9428542B2/en
Priority to HK15103034.5A priority patent/HK1202553B/en
Priority to EA201491479A priority patent/EA201491479A1/ru
Priority to KR1020147025188A priority patent/KR20140126739A/ko
Priority to CA2860581A priority patent/CA2860581A1/en
Priority to PCT/CN2013/071100 priority patent/WO2013117137A1/en
Priority to JP2014555064A priority patent/JP5872074B2/ja
Priority to AU2013218441A priority patent/AU2013218441A1/en
Priority to EP13746137.2A priority patent/EP2812343B1/en
Publication of CN103242413A publication Critical patent/CN103242413A/zh
Priority to ZA2014/05819A priority patent/ZA201405819B/en
Application granted granted Critical
Publication of CN103242413B publication Critical patent/CN103242413B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201310014849.XA 2012-02-08 2013-01-15 Lupane三萜系衍生物及其药学用途 Active CN103242413B (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN201310014849.XA CN103242413B (zh) 2012-02-08 2013-01-15 Lupane三萜系衍生物及其药学用途
JP2014555064A JP5872074B2 (ja) 2012-02-08 2013-01-30 ルパントリテルペノイド誘導体およびその薬学的使用
HK15103034.5A HK1202553B (en) 2012-02-08 2013-01-30 Lupane triterpenoid derivatives and pharmaceutical use thereof
EA201491479A EA201491479A1 (ru) 2012-02-08 2013-01-30 Производные лупановых тритерпеноидов и их фармацевтическое применение
KR1020147025188A KR20140126739A (ko) 2012-02-08 2013-01-30 루판 트리테르페노이드 유도체 및 이의 약제학적 용도
CA2860581A CA2860581A1 (en) 2012-02-08 2013-01-30 Lupane triterpenoid derivatives and pharmaceutical use thereof
BR112014018953A BR112014018953A8 (pt) 2012-02-08 2013-01-30 Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
US14/374,832 US9428542B2 (en) 2012-02-08 2013-01-30 Lupane triterpenoid derivatives and pharmaceutical use thereof
AU2013218441A AU2013218441A1 (en) 2012-02-08 2013-01-30 Lupane triterpenoid derivatives and pharmaceutical use thereof
EP13746137.2A EP2812343B1 (en) 2012-02-08 2013-01-30 Lupane triterpenoid derivatives and pharmaceutical use thereof
PCT/CN2013/071100 WO2013117137A1 (en) 2012-02-08 2013-01-30 Lupane triterpenoid derivatives and pharmaceutical use thereof
ZA2014/05819A ZA201405819B (en) 2012-02-08 2014-08-07 Lupane triterpenoid derivatives and pharmaceutical use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201210027090.4 2012-02-08
CN201210027090 2012-02-08
CN2012100270904 2012-02-08
CN201310014849.XA CN103242413B (zh) 2012-02-08 2013-01-15 Lupane三萜系衍生物及其药学用途

Publications (2)

Publication Number Publication Date
CN103242413A CN103242413A (zh) 2013-08-14
CN103242413B true CN103242413B (zh) 2015-08-26

Family

ID=48922317

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310014849.XA Active CN103242413B (zh) 2012-02-08 2013-01-15 Lupane三萜系衍生物及其药学用途

Country Status (11)

Country Link
US (1) US9428542B2 (cg-RX-API-DMAC7.html)
EP (1) EP2812343B1 (cg-RX-API-DMAC7.html)
JP (1) JP5872074B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140126739A (cg-RX-API-DMAC7.html)
CN (1) CN103242413B (cg-RX-API-DMAC7.html)
AU (1) AU2013218441A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014018953A8 (cg-RX-API-DMAC7.html)
CA (1) CA2860581A1 (cg-RX-API-DMAC7.html)
EA (1) EA201491479A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013117137A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201405819B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
AU2015346303B2 (en) * 2014-11-14 2018-03-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
US9914747B2 (en) 2014-11-14 2018-03-13 VIIV Healthcare UK (No.5) Limited Extended betulinic acid analogs
RU2017118576A (ru) * 2014-11-14 2018-12-14 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД C-17-арил-замещённые аналоги бетулиновой кислоты
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
WO2018029602A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-28 heterocycle derivatives as hiv inhibitors
WO2018029604A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
WO2018029610A1 (en) * 2016-08-09 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-17 n-amide derivatives as hiv inhibitors
WO2018065930A1 (en) * 2016-10-05 2018-04-12 Hetero Labs Limited C-3 triterpenone with c-17 reverse amide derivatives as hiv inhibitors
WO2018069857A1 (en) * 2016-10-12 2018-04-19 Hetero Labs Limited C-3 novel triterpenone with c-17 reverse amide heterocycle derivatives as hiv inhibitors
WO2019150300A1 (en) 2018-02-02 2019-08-08 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
CN114369134B (zh) * 2020-10-15 2024-12-31 江西青峰药业有限公司 一种Lupane三萜系衍生物葡甲胺盐无定型物及其制备方法和应用
CN114369136A (zh) * 2020-10-15 2022-04-19 江西青峰药业有限公司 一种Lupane三萜系衍生物的碱加成盐及其应用
CN115504947B (zh) * 2022-08-23 2024-04-26 山东和源制药有限公司 一种呋喃酮酸的制备方法
CN116041415B (zh) * 2023-02-01 2023-08-18 吉林农业大学 一种裂环羽扇豆烷衍生物及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127364A2 (en) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008057420A2 (en) * 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
WO2009073818A1 (en) * 2007-12-04 2009-06-11 Myriad Genetics, Inc. Compounds and therapeutic use thereof
CA2711424A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
AU2008342536A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel C-21-keto lupane derivatives preparation and use thereof
SG182769A1 (en) 2010-02-11 2012-09-27 Glaxosmithkline Llc Derivatives of betulin
JO3387B1 (ar) * 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين

Also Published As

Publication number Publication date
KR20140126739A (ko) 2014-10-31
CN103242413A (zh) 2013-08-14
JP5872074B2 (ja) 2016-03-01
JP2015505545A (ja) 2015-02-23
EP2812343A1 (en) 2014-12-17
US20150011517A1 (en) 2015-01-08
EP2812343B1 (en) 2019-03-13
WO2013117137A1 (en) 2013-08-15
BR112014018953A8 (pt) 2017-07-11
US9428542B2 (en) 2016-08-30
AU2013218441A1 (en) 2014-07-24
CA2860581A1 (en) 2013-08-15
BR112014018953A2 (cg-RX-API-DMAC7.html) 2017-06-20
EP2812343A4 (en) 2015-12-02
EA201491479A1 (ru) 2014-11-28
HK1202553A1 (en) 2015-10-02
ZA201405819B (en) 2015-12-23

Similar Documents

Publication Publication Date Title
CN103242413A (zh) Lupane三萜系衍生物及其药学用途
EP3567035B1 (en) N-substituted 2,5-dioxo-azoline compounds for use in the treatment of cancer
JP6091520B2 (ja) ベツリンのプロペン酸誘導体
AU2017254522A1 (en) Compounds and compositions for treating conditions associated with NLRP activity
EP3796975B1 (en) Sulfonylaminobenzamide derivatives
WO2020042995A1 (zh) 一种高活性sting蛋白激动剂化合物
CN113912589A (zh) 抑制并诱导蛋白降解的化合物
WO2017147312A1 (en) Combination therapies for treatment of spinal muscular atrophy
WO2023025324A1 (zh) 作为p53调节剂的化合物
CN105051008A (zh) 胍基苯甲酸酯化合物
CN108992453A (zh) 一类ocotillol型皂苷元衍生物的肿瘤耐药逆转的新用途
WO2022143424A1 (zh) 一种多环吡啶酮衍生物和药物组合物及其应用
WO2018072707A1 (zh) 芳香族醚类衍生物、其制备方法及其在医药上的应用
WO2023198180A1 (zh) Egfr降解剂
CN107074876B (zh) 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途
CN104844679A (zh) 白桦脂醇的衍生物
CA3099051C (en) Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
HK1202553B (en) Lupane triterpenoid derivatives and pharmaceutical use thereof
HK40049106B (en) Sulfonylaminobenzamide derivatives
HK40049106A (en) Sulfonylaminobenzamide derivatives
WO2025247386A1 (zh) 一种n-烷氧基乙酰胺类化合物、其药物组合物及其应用
HK40004367A (en) Compounds and compositions for treating conditions associated with nlrp activity
HK40004367B (en) Compounds and compositions for treating conditions associated with nlrp activity
CN108026139A (zh) 用于预防或治疗hiv感染的白桦脂醇衍生物
CN108026140A (zh) 用于预防或治疗hiv感染的白桦脂醇衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: LU FENG FENG QIAODI

Free format text: FORMER OWNER: FENG QIAODI

Effective date: 20140106

Owner name: JIANGXI QINGFENG PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: LU FENG

Effective date: 20140106

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 200336 CHANGNING, SHANGHAI TO: 341000 GANZHOU, JIANGXI PROVINCE

TA01 Transfer of patent application right

Effective date of registration: 20140106

Address after: 341000 Jiangxi province Zhanggong District of Ganzhou City, Shahe Industrial Park

Applicant after: Jiangxi Qingfeng Pharmaceutical Co., Ltd.

Applicant after: Lu Feng

Applicant after: Feng Qiaodi

Address before: 200336, room 6, No. 288, Lane 622, Qingxi Road, Shanghai, Changning District

Applicant before: Lu Feng

Applicant before: Feng Qiaodi

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20180109

Address after: 341000 Jiangxi province Zhanggong District of Ganzhou City, Shahe Industrial Park

Co-patentee after: Shanghai De Novo Pharmatech Co Ltd.

Patentee after: Jiangxi Qingfeng Pharmaceutical Co., Ltd.

Address before: 341000 Jiangxi province Zhanggong District of Ganzhou City, Shahe Industrial Park

Co-patentee before: Lu Feng

Patentee before: Jiangxi Qingfeng Pharmaceutical Co., Ltd.

Co-patentee before: Feng Qiaodi